AR009672A1 - Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par - Google Patents

Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par

Info

Publication number
AR009672A1
AR009672A1 ARP970106029A ARP970106029A AR009672A1 AR 009672 A1 AR009672 A1 AR 009672A1 AR P970106029 A ARP970106029 A AR P970106029A AR P970106029 A ARP970106029 A AR P970106029A AR 009672 A1 AR009672 A1 AR 009672A1
Authority
AR
Argentina
Prior art keywords
naftil
trifluorometil
fenil
etil
tetrahydropyridine
Prior art date
Application number
ARP970106029A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR009672A1 publication Critical patent/AR009672A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP970106029A 1996-12-23 1997-12-19 Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par AR009672A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (1)

Publication Number Publication Date
AR009672A1 true AR009672A1 (es) 2000-04-26

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970106029A AR009672A1 (es) 1996-12-23 1997-12-19 Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par

Country Status (38)

Country Link
EP (1) EP0950050B1 (en:Method)
JP (2) JP4499188B2 (en:Method)
KR (1) KR100586670B1 (en:Method)
CN (1) CN1129580C (en:Method)
AR (1) AR009672A1 (en:Method)
AT (1) ATE307802T1 (en:Method)
AU (1) AU736697B2 (en:Method)
BR (1) BR9714081A (en:Method)
CA (1) CA2275596C (en:Method)
CO (1) CO5070688A1 (en:Method)
CZ (1) CZ296689B6 (en:Method)
DE (1) DE69734460T2 (en:Method)
DK (1) DK0950050T3 (en:Method)
DZ (1) DZ2383A1 (en:Method)
EE (1) EE04188B1 (en:Method)
EG (1) EG21567A (en:Method)
ES (1) ES2251038T3 (en:Method)
FR (1) FR2757543B1 (en:Method)
HR (1) HRP970699B1 (en:Method)
HU (1) HU227425B1 (en:Method)
IL (1) IL129938A (en:Method)
IN (1) IN186976B (en:Method)
IS (1) IS2357B (en:Method)
MY (1) MY118015A (en:Method)
NO (1) NO312364B1 (en:Method)
NZ (1) NZ336130A (en:Method)
PL (1) PL190494B1 (en:Method)
RS (1) RS49882B (en:Method)
RU (1) RU2192416C2 (en:Method)
SA (1) SA98180971B1 (en:Method)
SI (1) SI0950050T1 (en:Method)
SK (1) SK285088B6 (en:Method)
TR (1) TR199901363T2 (en:Method)
TW (1) TW518322B (en:Method)
UA (1) UA60324C2 (en:Method)
UY (1) UY24825A1 (en:Method)
WO (1) WO1998028271A1 (en:Method)
ZA (1) ZA9711576B (en:Method)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US9272068B2 (en) 2010-03-12 2016-03-01 Nippon Shokubai Co., Ltd. Process for producing water-absorbing resin
ES2604405T3 (es) * 2011-04-15 2017-03-06 Emcure Pharmaceuticals Limited Un procedimiento para rilpivirina mejorado

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
ATE307802T1 (de) 2005-11-15
FR2757543B1 (fr) 1999-04-02
BR9714081A (pt) 2000-05-09
EE9900264A (et) 2000-02-15
AU5668498A (en) 1998-07-17
EG21567A (en) 2001-12-31
RS49882B (sr) 2008-08-07
WO1998028271A1 (fr) 1998-07-02
IN186976B (en:Method) 2001-12-22
EP0950050B1 (fr) 2005-10-26
CZ296689B6 (cs) 2006-05-17
NO993076L (no) 1999-06-22
SA98180971B1 (ar) 2006-09-13
DZ2383A1 (fr) 2002-12-28
ES2251038T3 (es) 2006-04-16
IS2357B (is) 2008-04-15
NO993076D0 (no) 1999-06-22
CZ229299A3 (cs) 1999-09-15
PL334256A1 (en) 2000-02-14
PL190494B1 (pl) 2005-12-30
CA2275596C (en) 2005-10-11
HUP0001387A2 (hu) 2000-09-28
TR199901363T2 (xx) 1999-08-23
IS5076A (is) 1999-06-10
SK285088B6 (sk) 2006-06-01
RU2192416C2 (ru) 2002-11-10
SK82899A3 (en) 1999-12-10
KR100586670B1 (ko) 2006-06-07
CN1129580C (zh) 2003-12-03
DE69734460T2 (de) 2006-07-06
NZ336130A (en) 2001-01-26
IL129938A (en) 2004-06-20
HRP970699A2 (en) 1998-10-31
IL129938A0 (en) 2000-02-29
DK0950050T3 (da) 2006-01-23
FR2757543A1 (fr) 1998-06-26
EP0950050A1 (fr) 1999-10-20
HRP970699B1 (en) 2007-03-31
AU736697B2 (en) 2001-08-02
KR20000069504A (ko) 2000-11-25
JP4499188B2 (ja) 2010-07-07
CO5070688A1 (es) 2001-08-28
EE04188B1 (et) 2003-12-15
HUP0001387A3 (en) 2002-03-28
MY118015A (en) 2004-08-30
HK1024002A1 (en) 2000-09-29
JP2009197022A (ja) 2009-09-03
CN1241180A (zh) 2000-01-12
TW518322B (en) 2003-01-21
YU28999A (sh) 2003-01-31
UA60324C2 (uk) 2003-10-15
SI0950050T1 (sl) 2006-04-30
JP2001507012A (ja) 2001-05-29
NO312364B1 (no) 2002-04-29
CA2275596A1 (en) 1998-07-02
HU227425B1 (en) 2011-05-30
ZA9711576B (en) 1998-06-25
DE69734460D1 (de) 2005-12-01
UY24825A1 (es) 1998-04-21

Similar Documents

Publication Publication Date Title
CO5011099A1 (es) Formulaciones en polvo en estado cristalino estable
ES2158778B1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
NO954400L (no) Substituerte pyrrolidin-3-yl-alkyl-piperidiner som er anvendbare som tachykininantagonister
DE69904302D1 (de) Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
GT199900119A (es) Jarabe antihistaminico estabilizado.
AR077416A2 (es) Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos
CO5280050A1 (es) Desnaturalizantes para las sales aminas simpaticomimeticas
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
DK1206467T3 (da) N-heterocykliske derivater som NOS-inhibitorer
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
AR026102A1 (es) Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion
DK0726893T3 (da) Hidtil ukendte 4-piperidinyl-substituerede lactamer som neurokinon 2-receptor-antagonister til behandling af astma
DE602004011790D1 (de) Meldoniumsalze, verfahren zu deren herstellung und auf ihnen basierende pharmazeutische zusammensetzung
AR059409A1 (es) Forma cristalina del succinato de 1-[2-(2-cloro-4-{[r-2-hidroxi-2-(8-hidroxi-2-oxo-1, 2-dihidroquinolin-5-il) etilamino] metil}-5- metoxifenilcarbamoil) etil] piperidin-4-il ester del acido bifenil-2-il-carbamico, una combinacion y una composicion farmaceutica que los contiene y el uso de la misma e
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
UY27410A1 (es) Formas novedosas crudas cristalinas
AR017754A1 (es) Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
AR027360A1 (es) Composicion farmaceutica
AR030203A1 (es) Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario
ES2046671T3 (es) Un procedimiento para la preparacion de tetrahidroimidazo(1,4)benzodiazepin-2-tionas.
AR009672A1 (es) Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par
BRPI0411308A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
NO20060379L (no) Den polymorfe form av 4-[6-acetyl-3-[3-(4-acetyl-3-hydroksy-2-propylfenyltio)propoksy]-2-propylfenoksybutansyre
AR030416A1 (es) COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
CO4700300A1 (es) Procedimiento para preparar olanzapina

Legal Events

Date Code Title Description
FC Refusal